WE are an ITALIAN BIOTECH COMPANY

that is developing

HIGHLY SENSITIVE SALIVARY MOLECULAR BIOSENSORS

to be used in Point-of-Care Applications

OUR TECHNOLOGY

Technology Femtorays

Femtorays Technologies (FTH) is an innovative SME located in the Trentino region that possesses a patented technique for detecting dispersed molecules in a fluid, based on integrated optoelectronic technology, including a Silicon Photonics chip with a series of miniaturized active sensors, a low-noise electronic circuit for reading the active sensors, and a software for interpreting and modeling the data.

FTH photonic multiplexing sensor system is based on arrays of biosensors controlled by a closed-loop locking of their relevant optical parameters. This was demonstrated to achieve superior sensitivity and response time thus increasing existing systems’ capabilities by several orders of magnitude up to the unprecedented label-free detection of single-molecules.

FTH’s patented technology utilizes a single, external laser source to drive all sensors and local on-chip modulators on each sensor to lock the optical parameter of interest to its initial state. The variation of the feedback signal over time is thus an accurate representation of the optical parameter shift of each sensor that is caused by biosensing.

Bio-functionalization process

The term “functionalization” refers to a process that allows stable, selective, and repetitive binding of a biorecognition element to the active surface of the sensors, which in turn is capable of recognizing a specific target analyte dispersed in the fluid to which the chip is exposed.

femtorays-01TEC_functionalization_scheme

APPLICATIONS

Femtorays-high-sensitive salivary diagnostic kit for POC application

FTH’s lab-on-chip: a high sensitivity/selectivity multiplex test at low-cost for point of care applications.

Nanometer scale design technology featuring exceptional scalability, robustness and integrability for high-volume production. Availability of low-cost, fast and reliable PoC diagnostic devices that do not require specialized personnel or equipment is a key factor enabling

    • rapid provision of results in acute syndromes to support clinical pathway decisions even before reaching the hospital, and
    • fast mass screening procedures.

Following validation and clinical trials, millions of patients will have faster access to the benefits of FTH innovative point-of-care technology which will help improve the quality of the healthcare service, decrease direct and indirect healthcare costs, reduce the use of unnecessary treatments and save lives.

ABOUT US

Dr. Carlo Guardiani

Founder and CEO
Femtorays - Nicola Dragone

Ing. Nicola Dragone

Founder and CSO
Femtorays - Pietro Mortini

Prof. Pietro Mortini

Founder and Medical Advisor
Femtorays - Mattia Mancinelli

Dr. Mattia Mancinelli PhD

Photonics R&D
Femtorays - Niccolo Ardoino

Ing. Niccolò Ardoino

Surface Biofunctionalization
Femtorays - Rachele Favaretto

Dr. Rachele Favaretto

Physical Modelling

Dr. Nicola Bellotto PhD

Surface Biofunctionalization

CURRENT INVESTORS

FTH Srl (Femtorays) is a an Innovative SME (PMI Innovativa) existing under the laws of Italy since 2017.

FTH is supported by a solid group of investors including the Founders (Prof. P. Mortini, Nicola Dragone and Carlo Guardiani), OMR Holding, Trentino Sviluppo, and Caltech among others.

Femtorays IP Portfolio and Partnerhips

FTH directly or indirectly holds over 12 patents in the field of molecular detection and collaborates with several key players such as Fondazione Bruno Kessler, Indivenire, the University of Trento and other public and private institutions.

CONTACT

FTH Srl

Via Sommarive 18, Povo (Trento) 38123, Italy

    provincia-autonoma-ti-Trento-femtorays-3

    Partially supported by LP 6/99 e ss.mm. Provincia Autonoma di Trento.